comparemela.com

Latest Breaking News On - Seog kim - Page 1 : comparemela.com

Trio partner to tackle maritime decarbonisation

Hanwha Ocean, Hanwha Aerospace and Amogy have teamed up to tackle maritime decarbonisation.

New jerseyUnited statesHanwha oceanHyoung seog kimAnastasija kuprijanovaMaritime business development at amogySystem business group at hanwha aerospaceHanwha aerospaceSeog kimExecutive vice presidentE propulsion system business groupNet zeroDecarbonisation summitMaritime business developmentEco friendly energy source including strengthsLectrical power system including hanwha aerospace

Hanwha Ocean invests into ammonia technology with Amogy

Hanwha Ocean has partnered with sibling company Hanwha Aerospace to use Amogy's ammonia cracking technology for fuel-cell powered ships.

Hanwha oceanHyoung seog kimHanwha groupCompany profilesCompany profileHanwha aerospaceSeog kimFortescue green pioneer

Anbalcabtagene Autoleucel Generates Responses in Relapsed/Refractory LBCL

The novel, autologous, anti-CD19 CAR T-cell therapy anbalcabtagene autoleucel produced durable responses and was well tolerated in patients with relapsed/refractory large B-cell lymphoma.

Soult ukpyolsiSouth koreaSeog kimDivision of hematologyOncology at samsun medical centerInternational conference on malignant lymphomaAnnualinternational conferenceWon seog kimSamsun medical centerInternational conferenceMalignant lymphomaCart cell therapy

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and. | June 9, 2023

United statesNew yorkBaden wübergSoult ukpyolsiSouth koreaArtiva alloAlexander fudukidisArndt schotteliusSeog kimJens pahlMary beth sandinArtiva biotherapeutics incInternational conference on malignant lymphomaGlobenewswire incUniversity of texas md anderson cancer centerDrug administration

Affimed Announces Acceptance of Abstracts at the 17th

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic.

United statesBaden wübergNew yorkSoult ukpyolsiSouth koreaArtiva alloArndt schotteliusJens pahlMary beth sandinAlexander fudukidisSeog kimDrug administrationUniversity of texas md anderson cancer centerArtiva biotherapeutics incOncology at samsung medical centerInternational conference on malignant lymphoma

vimarsana © 2020. All Rights Reserved.